SAGE 324
Alternative Names: BIIB-124; SAGE-324Latest Information Update: 20 Feb 2025
At a glance
- Originator SAGE Therapeutics
- Class Antiepileptic drugs; Antiparkinsonians; Small molecules
- Mechanism of Action GABA A receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Epilepsy
- No development reported Parkinson's disease
- Discontinued Essential tremor
Most Recent Events
- 20 Feb 2025 SAGE 324 is still in phase I trials for Epilepsy in the US (Sage Therapeutics pipeline, February 2025)
- 11 Feb 2025 Biogen and Sage Therapeutics terminates the collaboration to develop and commercialize SAGE 324 for Essential tremors, Epilepsy and Parkinson's disease (SAGE Therapeutics pipeline, February 2025)
- 11 Feb 2025 Sage Therapeutics plans a phase II trial in Epilepsy (Sage Therapeutics pipeline, February 2025)